Clinical Trials for Cystic Fibrosis

Researchers around the world are working to develop new drugs for the treatment of cystic fibrosis. These new treatments must go through a rigorous trial process, testing their safety and efficacy, before they are made available to the people who need them. Patients play a critical role in the development of new treatments through their participation in these clinical trials.

Below are ongoing clinical trials for cystic fibrosis that have been organized into various categories by the Cystic Fibrosis Foundation.

3
phase 1
19
phase 2
26
phase 3
9
other*
57
total
CFTR Modulation
drugKalydeco03418
drugAtaluren00202
drugVX-809 + ivacaftor11204
drugVX-661 + ivacaftor02002
drugN602210001
Restore Airway Surface Liquid
drugHypertonic Saline01023
drugBronchitol00101
Mucus Alteration
drugPulmozyme00112
drugAlpha 1 Anti-Trypsin01001
drugKB001-A02002
drugSildenafil01001
Anti-Infective
drugInhaled Tobramycin01102
drugAzithromycin01214
drugCayston®01719
drugTIP00033
drugLevofloxacin11204
drugArikace™02305
drugAeroVanc™01001
drugNutrition01001
drugLiprotamase00101

* Phase 4 or compassionate care study
** Only ongoing studies are included (recruiting, pending recruitment or active, but not yet recruiting)

Are we missing a trial?